Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.54 |
| ▸ | GABRD | O14764 | 3/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.54 |
| ▸ | GABRE | P78334 | 3/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7353965 | 1.00 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7350338 | 1.00 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL26547294 | 0.93 | ALDH1A1 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11515287 | 0.91 | ALDH1A1 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4037012 | 0.86 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL932317 | 0.86 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL288345 | 0.86 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27963271 | 0.85 | ENPEP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1354935 | 0.81 | GABRP (0.73) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18222603 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6342529-B1 | ANTIDEPRESSANTS | NORTHWESTERN UNIVERSITY | 2002-01-29 | — | — | US | claimed |
| US-6291526-B1 | TREATING A PATIENT HAVING PARKINSON'S DISEASE BY ADMINISTERING 4-AMINO-3-(2-METHYLPROPYL)BUTANOIC ACID. | NORTHWESTERN UNIVERSITY | 2001-09-18 | — | — | US | claimed |
| US-6262120-B1 | ADMINISTERING ANTIPSYCHOTIC EFFECTIVE AMOUNT OF COMPOUND 4-AMINO-3-(2-METHYLPROPYL) BUTANOIC ACID FOR THERAPY OF PSYCHOTIC DISORDERS | NORTHWESTERN UNIVERSITY | 2001-07-17 | — | — | US | claimed |
| US-6197819-B1 | Gamma amino butyric acid analogs and optical isomers | NORTHWESTERN UNIVERSITY | 2001-03-06 | — | — | US | claimed |
| WO-1992009560-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1992-06-11 | — | — | WO | claimed |
| US-RE48948-E1 | Clonidine compounds in a biodegradable polymer | WARSAW ORTHOPEDIC, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-9968572-B2 | Clonidine and GABA compounds in a biodegradable polymer carrier | WARSAW ORTHOPEDIC, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9867910-B2 | Clonidine compounds in a biodegradable fiber | WARSAW ORTHOPEDIC, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9610243-B2 | Clonidine compounds in a biodegradable polymer | WARSAW ORTHOPEDIC, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9301946-B2 | Clonidine and GABA compounds in a biodegradable polymer carrier | WARSAW ORTHOPEDIC, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9066853-B2 | Clonidine compounds in a biodegradable fiber | WARSAW ORTHOPEDIC, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130216602-A1 | CLONIDINE COMPOUNDS IN A BIODEGRADABLE POLYMER | WARSAW ORTHOPEDIC, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20090069427-A1 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP | PFIZER INC. | 2009-03-12 | — | — | US | disclosed |
| EP-1993529-A1 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP | Pfizer Products Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008128775-A2 | STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE | RATIOPHARM GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007102058-A1 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP | PFIZER PRODUCTS INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-6414024-B1 | HUNTINGTON'S DISEASE | NORTHWESTERN UNIVERSITY | 2002-07-02 | — | — | US | disclosed |
| EP-0641330-B1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | UNIV NORTHWESTERN (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-1992009560-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009560-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069427-A1 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP | EBP, CACNG2, SCNN1G | GABRP 60/4885GABRD 393/4885GABRA1 195/4885 |
| US-20130216602-A1 | CLONIDINE COMPOUNDS IN A BIODEGRADABLE POLYMER | SNCA, SUCNR1, SMN1; SMN2 | GABRP 761/4885GABRD 29/4885GABRA1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.